In conclusion, our study found that gemigliptin effectively ameliorates hepatic steatosis, inflammation, and fibrosis in an MCD diet–induced NASH model mice by enhancing autophagy through an increase in ULK1 expression. Here, ULK1 is linked to fatty liver disease.